Loading stock…

Sarepta Therapeutics, Inc. (SRPT) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Sarepta Therapeutics, Inc.

SRPTMarket cap $1.85BPrice $17.5

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops gene therapies for rare, devastating muscle-wasting diseases like Duchenne muscular dystrophy. It won the first-ever FDA approval for a Duchenne gene therapy, turning a once-untreatable childhood diagnosis into a treatable condition.

In Bastion Portfolios?

52W Return-22%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+33%10

Revenue Forecast

Rev CAGR (1y)-16%1

Rev CAGR (3y)-15%1

Rev CAGR (5y)-11%1

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2-53%1

EPS Growth Y+3+1%4

Quality

Margins

EBIT Margin-3%1

Net Income Margin-7%1

Free Cash Flow Margin4%4

Debt

Net Debt/EBITDAna–

Efficiency

ROE-9%1

ROA-4%1

Earnings Stability44

GEAR+VERY WEAK5

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)99

P/E Ratio (Forward 3y)89

P/BV1.29

EV Multiples

EV/EBITDA Fwd510

EV/EBIT Fwd510

Yield

Free Cash Flow Yield4.4%6

Dividend Yieldna–

Momentum

Short term

1 month return-16%1

3 month return-13%3

YTD return-19%2

Mid term

Price vs 52wHigh69%3

1 year return-25%2

Long term

3 year return-86%1

5 year return-82%1

Risk Shield

Price Risk

Beta1.42

Volatility81%1

Free Cash Flow

Free Cash Flow Margin4%4

Free Cash Flow Yield4.4%6

Quality

ROCE-2%1

Earnings Stability44

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

SRPTSarepta Therapeutics

Revenue FY25$2.2B

GROWTH RATING↗

VERY WEAK7 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+33%10

Revenue, next 1Y-16%1

Revenue, next 3Y, CAGR-15%1

Revenue, next 5Y, CAGR-11%1

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E-53%1

EPS growth, FY28E+1%4

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 33%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

WATCH

None flagged.

WEAKNESSES

Growth is the weak spot here, trailing 93% of companies worldwide.

Revenue is set to shrink 15%/yr over the next 3 years, behind most of the market.1/10

Revenue grew 33%/yr over the last 3 years, but it is set to shrink 15%/yr from here.

Over five years revenue is set to shrink 11%/yr, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business heading into decline. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK4 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-16%1

3-month return-13%3

YTD return-19%2

MID & LONG-TERM▾SCORE

% of 52-week high69%3

1-year return-25%2

3-year return-86%1

5-year return-82%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-86% over three years and -82% over five), behind 90% of the market.

It's down 25% over the past year, now 31% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-16%), over three months (-13%) and so far this year (-19%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Sarepta Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

SRPTSarepta Therapeutics

Revenue FY25$2.2B

GROWTH RATING↗

VERY WEAK7 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+33%10

Revenue, next 1Y-16%1

Revenue, next 3Y, CAGR-15%1

Revenue, next 5Y, CAGR-11%1

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E-53%1

EPS growth, FY28E+1%4

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 33%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

WATCH

None flagged.

WEAKNESSES

Growth is the weak spot here, trailing 93% of companies worldwide.

Revenue is set to shrink 15%/yr over the next 3 years, behind most of the market.1/10

Revenue grew 33%/yr over the last 3 years, but it is set to shrink 15%/yr from here.

Over five years revenue is set to shrink 11%/yr, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business heading into decline. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK4 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-16%1

3-month return-13%3

YTD return-19%2

MID & LONG-TERM▾SCORE

% of 52-week high69%3

1-year return-25%2

3-year return-86%1

5-year return-82%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-86% over three years and -82% over five), behind 90% of the market.

It's down 25% over the past year, now 31% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-16%), over three months (-13%) and so far this year (-19%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Sarepta Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community